Apoliktos accelerates personalized cancer therapy by rapidly creating patient-specific therapeutic antibodies in 3-7 days. Their platform uses a modular library of neoantigen binders and antibody backbones to design and synthesize targeted treatments, enabling faster intervention for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer patients face significant delays in receiving personalized therapies following diagnosis, hindering timely and effective treatment. The current development cycle for patient-specific treatments is often too lengthy to align with the urgent needs of individuals with progressive diseases.
Solution
Apoliktos is developing a platform for rapid, patient-specific therapeutic antibody creation, aiming to deliver personalized cancer treatments from diagnosis to therapy within 3-7 days. The platform leverages a modular library of neoantigen binders and antibody backbones, enabling the rapid design and synthesis of targeted therapeutic antibodies. This approach facilitates a significantly accelerated treatment pathway, addressing the critical need for prompt intervention in cancer care. The process involves physician collaboration for patient stratification, followed by the development of a personalized approach using specific tumor-mutation binders combined with immunotherapy, with the aim of improving patient outcomes.
Target Audience
The primary target audience includes oncologists and healthcare providers seeking accelerated personalized treatment options for cancer patients, as well as pharmaceutical companies interested in novel drug development platforms.
Features
- Rapid development of personalized therapeutic antibodies from diagnosis to therapy in 3-7 days.
- Utilizes a modular library of neoantigen binders for targeted therapy development.
- Employs a modular library of antibody backbones for diverse therapeutic applications.
- Facilitates patient stratification in collaboration with physicians.
- Integrates tumor-mutation binders with immunotherapy for enhanced treatment efficacy.
- Designed for bedside application to expedite treatment delivery.